A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in their mental abilities).
Condition or disease
Cognitive DisordersHIV Infections
Drug: Thioctic acidDrug: Selegiline hydrochloride
Patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active drug on an open-label basis. Patients must have seven clinic visits.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Antiretrovirals provided dose has been stable for at least 6 weeks prior to study entry.
Patients must have:
Mild to moderate cognitive impairment (problems with short term memory, concentration, and feeling slowed down).
No active opportunistic CNS infection.
Ability to give informed consent.
Prior antiretrovirals provided dose has been stable for at least the past 6 weeks.
Prior thioctic acid or deprenyl.
Patients with the following symptoms or conditions are excluded:
Severe premorbid psychiatric illness including schizophrenia and major depression that would interfere with study compliance.
Any other clinically significant condition or laboratory abnormality that would preclude participation on study.
Current participation in other drug studies.
Chemotherapy for malignancy.
Patients with the following prior conditions are excluded:
History of chronic neurological disorders such as serious head injury, documented stroke, multiple sclerosis, uncontrolled epilepsy, Tourette's syndrome, and other neurodegenerative processes such as Huntington's disease.
Prior participation in this study.
History of adverse reaction/allergy to thioctic acid or deprenyl.
Other investigational drugs within 30 days prior to study entry.